Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 3/2010

01-05-2010

Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy

Authors: Mario Scartozzi, Mirco Pistelli, Alessandro Bittoni, Riccardo Giampieri, Eva Galizia, Rossana Berardi, Luca Faloppi, Michela Del Prete, Stefano Cascinu

Published in: Current Oncology Reports | Issue 3/2010

Login to get access

Abstract

Although recent advances have been made, surgery still remains the mainstay of any curative treatment for gastric cancer patients, with radical gastrectomy representing the procedure of choice. However, patients with locally advanced disease show high rates of locoregional or distant recurrence even after potentially curative resections. According to global results presented in the setting of locally advanced resectable gastric carcinoma, perioperative chemotherapy may be considered a valuable option. On the other hand, clinical trials for advanced gastric cancer seem to suggest that a limit in efficacy has been reached for standard chemotherapy. Interesting data are expected from the development of targeted agents that, similarly to other cancer sites, showed appealing results in gastric cancer as well. Along with new effective therapeutic opportunities, better clinical and molecularly driven patient selection will represent the cornerstone of the global care for these patients.
Literature
1.
Hermans J, Bonekamp JJ, Bon MC, et al.: Adjuvant therapy after resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993, 11:1441–1447.PubMed
2.
Earle CC, Maroun JA: Adjuvant chemotherapy after resection for gastric cancer in non-Asian patients. Revisiting a meta-analysis of randomized trials. Eur J Cancer 1999, 35:1059–1064.
3.
Mari M, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis for published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000, 11:837–843.CrossRefPubMed
4.
Panzini I, Gianni L, Fattori PP, et al.: Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002, 88:21–27.PubMed
5.
Di Costanzo F, Gasperoni S, Manzione L, et al.: Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 2008, 100:388–398.CrossRefPubMed
6.
Bouche O, Ychou M, Burtin P, et al.: Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005, 16:1488–1497.CrossRefPubMed
7.
Bajetta E, Buzzoni R, Mariani L, et al.: Adjuvant chemotherapy in gastric cancer: 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002, 13:299–307.CrossRefPubMed
8.
Cascinu S, La bianca R, Barone C, et al.: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007, 99:601–607.
9.
• Buyse ME, Pignon J: Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. J Clin Oncol 2009, 27(Suppl 15):abstract 4539. This is the latest meta-analysis available about adjuvant treatment of gastric cancer. A small, but definite improvement in OS has been suggested, along with a tumor stage–related beneficial effect deriving from chemotherapy.
10.
Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725–730.CrossRefPubMed
11.
Macdonald JS, Benedetti J, Smalley S, et al.: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009, 27(Suppl 15):abstract 4515.
12.
Scartozzi M, Galizia E, Graziano F, et al.: Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. Br J Cancer 2005, 92:1051–1054.CrossRefPubMed
13.
Cunningham D, Allum WH, Stenning SP, et al.: MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11–20.CrossRefPubMed
14.
Boige V, Pignon J, Saint-Aubert B, et al.: Final results of randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. ASCO 2007, abstract 4510.
15.
Roth et al.: Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO). Presented at the World Congress on Gastrointestinal Cancer. Barcelona, Spain; June 28–July 1, 2007.
16.
Schuhmacher C, Schlag P, Lordick F, et al.: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: randomized EORTC phase III trial #40954. J Clin Oncol 2009, 27(Suppl 15):abstract 4510.
17.
Stahl M, Walz KM, Stuschke M, et al.: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27:851–856.CrossRefPubMed
18.
Cunningham D, Starling N, Rao S, et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36–46.CrossRefPubMed
19.
Kang YK, Kang WK, Shin DB, et al.: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009, 20:667–673.
20.
• Koizumi W, Narahara H, Hara T, et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215–221. This phase 3 randomized trial demonstrated the superiority of combined cisplatin-S1 over S1 in a Japanese population.
21.
Lenz HJ, Lee FC, Haller DG, et al.: Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007, 109:33–40.CrossRefPubMed
22.
• Ajani JA, Rodriquez W, Bodoky G, et al.: Randomized phase III trial for first line treatment of advanced gastric cancer. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS) [abstract 8]. Presented at 2009 Gastrointestinal Cancers Symposium, ASCO. San Francisco, CA; January 15–17, 2009. In this trial, cisplatin/S1 combination demonstrated an equivalent efficacy compared to cisplatin/5-FU, with an improved toxicity profile.
23.
Bozu N, Yamamoto S, Fukuda H, et al.: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009, 10:1063–1069.CrossRef
24.
Ajani J, Moiseyenko VM, Tjulandin S, et al.: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group. J Clin Oncol 2007, 25:3210–3216.CrossRefPubMed
25.
Tebbutt NC, Cummins MM, Sourjina T, et al.: Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 2010, In press.
26.
Capdevila J, Elez E, Macarulla T, et al.: Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009, 35:354–363.CrossRefPubMed
27.
Pinto C, Di Fabio F, Barone C, et al.: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009, 101:1261–1268.CrossRefPubMed
28.
Lordick F, Lorenzen S, Hegewisch-Becker S, et al.: Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group [abstract]. J Clin Oncol 2007, 25(Suppl 18):4526.
29.
Han SW, Oh DY, Im SA, et al.: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009, 100:298–304.CrossRefPubMed
30.
Kim C, Lee JL, Ryu MH, et al.: A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2009 Dec 9 (Epub ahead of print).
31.
Woell E, Greil R, Eisterer W, et al.: Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT) [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:4538.
32.
Pinto C, Di Fabio F, Siena S, et al.: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007, 18:510–517.CrossRefPubMed
33.
Kanzler S, Trarbach T, Seufferlein T, et al.: Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:4534.
34.
Yeh K, Hsu C, Hsu C, et al.: Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:4567.
35.
36.
Rao S, Starling N, Cunningham D, et al.: Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008, 99:868–874.CrossRefPubMed
37.
Doi T, Koizumi W, Siena S, et al.: Efficacy, tolerability and pharmacokinetics of gefitinib (Iressa, ZD1839) in pretreated patients with metastatic gastric cancer. Proc ASCO 2004, abstract 1036.
38.
Dragovich T, McCoy S, Urba SG, et al.: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006, 24:4922–4927.CrossRefPubMed
39.
Tanner M, Hollmen M, Junttila TT, et al.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:273–278.CrossRefPubMed
40.
Gravalos C, Marquez A, Garcia-Carbonero R, et al.: Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study [abstract 89]. Presented at the 2007 Gastrointestinal Cancers Symposium. Orlando, FL; January 19–21, 2007.
41.
Kang Y, Bang Y, Lordick F, et al.: Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity [abstract 11]. Presented at the 2008 Gastrointestinal Cancers Symposium. Orlando, FL; January 25–27, 2008.
42.
•• Van Cutsem E, Kang Y, Chung H, et al.: Efficacy results from the ToGA trial. A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER-2)-positive advanced gastric cancer (GC). J Clin Oncol (Meeting Abstracts) 2009, 27:LBA4509. This is the first phase 3 randomized clinical trial demonstrating a survival advantage with the addition of a molecularly targeted agent (trastuzumab) to standard chemotherapy in gastric cancer patients.
43.
Shan MA, Ramanathan RK, Ilson DH, et al.: Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24:5201–5206.CrossRef
44.
Kelsen D, Jhawer M, Ilson D, et al.: Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. J Clin Oncol (Meeting Abstracts) 2009, 27:4512.
45.
El-Rayes BF, Patel B, Zalupski M, et al.: A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. J Clin Oncol (Meeting Abstracts) 2009, 27:4563.
46.
Sun W, Powell ME, O’Dwyer P, et al.: A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). J Clin Oncol (Meeting Abstracts) 2009, 26:4535.
47.
Kim C, Lee J, Choi Y, et al.: Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. J Clin Oncol (Meeting Abstracts) 2009, 26:4559.
48.
Jhawer M, Kindler HL, Wainberg Z, et al.: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol (Meeting Abstracts) 2009, 26:4502.
49.
Yamada Y, Doi T, Muro K, et al.: Multicenter phase II study of everolimus in patients with treated metastatic gastric cancer: main results. In Proceedings of the American Society of Clinical Oncology 2009; Gastrointestinal Cancer Symposium. Abstract 77.
Metadata
Title
Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy
Authors
Mario Scartozzi
Mirco Pistelli
Alessandro Bittoni
Riccardo Giampieri
Eva Galizia
Rossana Berardi
Luca Faloppi
Michela Del Prete
Stefano Cascinu
Publication date
01-05-2010
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 3/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-010-0101-8

Other articles of this Issue 3/2010

Current Oncology Reports 3/2010 Go to the issue

ReviewPaper

The Emergence of Endoscopic Head and Neck Surgery

ReviewPaper

Current and Emerging Treatment Strategies for Anal Cancer

ReviewPaper

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma

Clinical Trial Report

Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks

ReviewPaper

Renal Cell Carcinoma: Where Will the State-of-the-Art Lead Us?

ReviewPaper

Evolving Treatment of Advanced Colorectal Cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits